Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
Andrés J M
AJ
Ferreri
Giuseppina P
GP
Dognini
Silvia
S
Govi
Roberto
R
Crocchiolo
Maria
M
Bouzani
Claudia R
CR
Bollinger
Michel
M
D'Incan
Emmanuel
E
Delaporte
Mehdi
M
Hamadani
Fabrice
F
Jardin
Magdalena
M
Martusewicz-Boros
Mauro
M
Montanari
Arpad
A
Szomor
Emanuele
E
Zucca
Franco
F
Cavalli
Maurilio
M
Ponzoni
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab